European Regulators Decline Approval for Lecanemab, Citing Insufficient Benefit Against Risks

Brussels, Belgium – In a significant decision that underscores the global complexities of approving novel treatments for early Alzheimer’s disease, an expert committee for the European Medicines Agency (EMA) has…

Alzheimer’s Research UK Renews Flagship Drug Discovery Alliance with Landmark £45 Million Investment, Signalling a New Era in Dementia Research

In a pivotal moment for global dementia research, Alzheimer’s Research UK (ARUK) has announced the significant renewal of its flagship Drug Discovery Alliance (DDA), committing up to £45 million in…

European Medicines Agency Rejects Lecanemab for Early Alzheimer’s Disease, Citing Insufficient Benefit-Risk Profile.

The European Medicines Agency (EMA), through its expert Committee for Medicinal Products for Human Use (CHMP), has delivered a significant blow to the global fight against Alzheimer’s disease, announcing its…